Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 41

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome

Jensen, M. Martin, Jia, Wanjian, Schults, Austin J., Isaacson, Kyle J., Steinhauff, Douglas, Green, Bryant, Zachary, B., Cappello, Joseph, Ghandehari, Hamidreza, Oottamasathien, Siam · 2019 · Biomaterials

Abstract

Interstitial cystitis (IC), also known as painful bladder syndrome, is a debilitating chronic condition with many patients failing to respond to current treatment options. Rapid clearance, mucosal coating, and tight epithelium create strong natural barriers that reduce the effectiveness of many pharmacological interventions in the bladder. Intravesical drug delivery (IDD) is the administration of therapeutic compounds or devices to the urinary bladder via a urethral catheter. Previous work in improving IDD for IC has focused on the sustained delivery of analgesics within the bladder and other small molecule drugs which do not address underlying inflammation and bladder damage. Therapeutic glycosaminoglycans (GAG) function by restoring the mucosal barrier within the bladder, promoting healing responses, and preventing irritating solutes from reaching the bladder wall. There is an unmet medical need for a therapy that provides both acute relief of symptoms while alleviating underlying physiological sources of inflammation and promoting healing within the urothelium. Semi-synthetic glycosaminoglycan ethers (SAGE) are an emerging class of therapeutic GAG with intrinsic anti-inflammatory and analgesic properties. To reduce SAGE clearance and enhance its accumulation in the bladder, we developed a silk-elastinlike protein polymer (SELP) based system to enhance SAGE IDD. We evaluated in vitro release kinetics, rheological properties, impact on bladder function, pain response, and bladder inflammation and compared their effectiveness to other temperature-responsive polymers including Poloxamer 407 and poly(lactic-co-glycolic acid)-poly(ethylene glycol). SAGE delivered via SELP-enhanced intravesical delivery substantially improved SAGE accumulation in the urothelium, provided a sustained analgesic effect 24 hrs. after administration, and reduced inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biomaterials.2019.119293

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 58

  1. Elbadawi, 1997, Interstitial cystitis: a critique of current concepts with a new proposal for pathologic diagnosis and pathogenesis, Urology, 49, 14, 10.1016/S0090-4295(99)80329-X · DOI · Paper page
  2. Lee, 2013, Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan, PLoS One, 8
  3. Nickel, 2012, Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device, Sci. Transl. Med., 4, 143ra100, 10.1126/scitranslmed.3003804 · DOI
  4. Parsons, 1994, Treatment of interstitial cystitis with intravesical heparin, Br. J. Urol., 73, 504, 10.1111/j.1464-410X.1994.tb07634.x · doi:10.1111/j.1464-410x.1994.tb07634.x
  5. Welk, 2008, Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin, Urology, 71, 67, 10.1016/j.urology.2007.09.067 · DOI
  6. Nickel, 2009, Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome, BJU Int., 103, 910, 10.1111/j.1464-410X.2008.08162.x · DOI
  7. Parsons, 2012, Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis, J. Sex. Med., 9, 207, 10.1111/j.1743-6109.2011.02542.x · doi:10.1111/j.1743-6109.2011.02542.x
  8. Lamarre, 2015, Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?, Transl. Androl. Urol., 4, 543
  9. Krhut, 2016, Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: a double-blind randomized pilot study, Scand. J. Urol., 50, 200, 10.3109/21681805.2015.1121406 · doi:10.3109/21681805.2015.1121406
  10. Chuang, 2017, A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation OnabotulinumtoxinA for interstitial cystitis/bladder pain syndrome, J. Urol., 198, 376, 10.1016/j.juro.2017.02.021 · DOI
  11. Pulsipher, 2017, Prevention of sinonasal inflammation by a synthetic glycosaminoglycan, Int. Forum Allergy Rhinol., 7, 177, 10.1002/alr.21865 · DOI
  12. Kaufman, 2010, State of the art in intravesical therapy for lower urinary tract symptoms, Rev. Urol., 12, e181
  13. GuhaSarkar, 2010, Intravesical drug delivery: challenges, current status, opportunities and novel strategies, J. Control. Release, 148, 147, 10.1016/j.jconrel.2010.08.031 · DOI · Paper page
  14. Zacchè, 2015, Novel targeted bladder drug-delivery systems: a review, Res. Rep. Urol., 7, 169
  15. Karimi, 2016, Temperature-responsive smart nanocarriers for delivery of therapeutic agents: applications and recent advances, ACS Appl. Mater. Interfaces, 8, 21107, 10.1021/acsami.6b00371 · DOI · Paper page
  16. Price, 2014, Controlled release from recombinant polymers, J. Control. Release, 190, 304, 10.1016/j.jconrel.2014.06.016 · DOI
  17. Ciofani, 2014, The potential of recombinant human elastin-like polypeptides for drug delivery, Expert Opin. Drug Deliv., 11, 1507, 10.1517/17425247.2014.926885 · doi:10.1517/17425247.2014.926885
  18. Megeed, 2002, Genetically engineered silk-elastinlike protein polymers for controlled drug delivery, Adv. Drug Deliv. Rev., 54, 1075, 10.1016/S0169-409X(02)00063-7 · DOI · Paper page
  19. Dandu, 2009, Silk–elastinlike protein polymer hydrogels: influence of monomer sequence on physicochemical properties, Polymer, 50, 366, 10.1016/j.polymer.2008.11.047 · DOI · Paper page
  20. Price, 2015, In vivo evaluation of matrix metalloproteinase responsive silk–elastinlike protein polymers for cancer gene therapy, J. Control. Release, 213, 96, 10.1016/j.jconrel.2015.06.022 · DOI
  21. Poursaid, 2016, Silk-elastinlike protein polymer liquid chemoembolic for localized release of doxorubicin and sorafenib, Mol. Pharm., 13, 2736, 10.1021/acs.molpharmaceut.6b00325 · DOI · Paper page
  22. Poursaid, 2015, In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization, Biomaterials, 57, 142, 10.1016/j.biomaterials.2015.04.015 · DOI · Paper page
  23. Price, 2014, Effect of shear on physicochemical properties of matrix metalloproteinase responsive silk-elastinlike hydrogels, J. Control. Release, 195, 92, 10.1016/j.jconrel.2014.07.044 · DOI
  24. Gustafson, 2013, Synthesis and characterization of a matrix-metalloproteinase responsive silk–elastinlike protein polymer, Biomacromolecules, 14, 618, 10.1021/bm3013692 · DOI
  25. Haider, 2005, Molecular engineering of silk-elastinlike polymers for matrix-mediated gene delivery: biosynthesis and characterization, Mol. Pharm., 2, 139, 10.1021/mp049906s · DOI
  26. Jensen, 2017, Silk-elastinlike protein polymers enhance the efficacy of a therapeutic glycosaminoglycan for prophylactic treatment of radiation-induced proctitis, J. Control. Release, 263, 46, 10.1016/j.jconrel.2017.02.025 · DOI · Paper page
  27. Price, 2012, Comparison of silk-elastinlike protein polymer hydrogel and poloxamer in matrix-mediated gene delivery, Int. J. Pharm., 427, 97, 10.1016/j.ijpharm.2011.09.037 · DOI
  28. Dandu, 2008, Characterization of structurally related adenovirus-laden silk-elastinlike hydrogels, J. Bioact. Compat Polym., 23, 5, 10.1177/0883911507085278 · DOI
  29. Gao, 2010, PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate, Drug Dev. Ind. Pharm., 36, 1131, 10.3109/03639041003680826 · DOI
  30. Yu, 2008, Injectable block copolymer hydrogels for sustained release of a PEGylated drug, Int. J. Pharm., 348, 95, 10.1016/j.ijpharm.2007.07.026 · DOI · Paper page
  31. Fakhari, 2017, Thermogelling properties of purified poloxamer 407, Heliyon, 3, 10.1016/j.heliyon.2017.e00390 · DOI · Paper page
  32. Jia, 2017, Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model, Am. J. Clin. Exp. Urol., 5, 10
  33. Oottamasathien, 2013, Physiological relevance of LL-37 induced bladder inflammation and mast cells, J. Urol., 190, 1596, 10.1016/j.juro.2013.01.002 · DOI
  34. Oottamasathien, 2011, A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides, J. Urol., 186, 1684, 10.1016/j.juro.2011.03.099 · DOI
  35. Rudick, 2009, Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis, BMC Urol., 9, 1, 10.1186/1471-2490-9-16 · DOI
  36. Cappelleri, 2009, Pain responder analysis: use of area under the curve to enhance interpretation of clinical trial results, Pain Pract., 9, 348, 10.1111/j.1533-2500.2009.00293.x · DOI
  37. Yu, 2014, Spontaneous voiding by mice reveals strain-specific lower urinary tract function to be a quantitative genetic trait, Am. J. Physiol. Physiol., 306, F1296, 10.1152/ajprenal.00074.2014 · DOI
  38. Erickson, 2006, Molecular Size Affects Urine Excretion of Pentosan Polysulfate, 175, 1143
  39. Faaij, 1999, The oral bioavailability of pentosan polysulphate sodium in healthy volunteers, Eur. J. Clin. Pharmacol., 54, 929, 10.1007/s002280050577 · doi:10.1007/s002280050577
  40. Davis, 2008, Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial, J. Urol., 179, 177, 10.1016/j.juro.2007.08.170 · doi:10.1016/j.juro.2007.08.170
  41. Cox, 2016, CUA guideline: diagnosis and treatment of interstitial cystitis/bladder pain syndrome, Can. Urol. Assoc. J., 10, E136, 10.5489/cuaj.3786 · DOI
  42. Zhang, 2011, Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea, PLoS One, 6
  43. Savage, 2016, A modified glycosaminoglycan, GM-0111, inhibits molecular signaling involved in periodontitis, PLoS One, 11, 10.1371/journal.pone.0157310 · DOI
  44. Martin Jensen, 2018, IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model, Cytokine, 110, 420, 10.1016/j.cyto.2018.05.012 · DOI
  45. Lin, 2016, Floating hydrogel with self-generating micro-bubbles for intravesical instillation, Materials, 9, E1005, 10.3390/ma9121005 · doi:10.3390/ma9121005
  46. Donin, 2017, Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility, Urol. Oncol. Semin. Orig. Investig., 35, 272
  47. Lin, 2017, Thermo reversible hydrogel based delivery of mitomycin C for treatment of upper tract urothelial carcinoma (UTUC), J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.e16089 · doi:10.1200/jco.2017.35.15_suppl.e16089
  48. Chen, 2017, Evaluating the voiding spot assay in mice: a simple method with complex environmental interactions, Am. J. Physiol. Physiol., 313, F1274, 10.1152/ajprenal.00318.2017 · DOI
  49. Jacobsen, 2012, Postsurgical food and water consumption, fecal corticosterone metabolites, and behavior assessment as noninvasive measures of pain in vasectomized BALB/c mice, J. Am. Assoc. Lab. Anim. Sci., 51, 69
  50. Janicki, 2015, Intravesical liposome drug delivery and IC/BPS, Transl, Androl. Urol., 4, 572
  51. Chuang, 2009, Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome, J. Urol., 182, 1393, 10.1016/j.juro.2009.06.024 · doi:10.1016/j.juro.2009.06.024
  52. Tyagi, 2017, Intravesical liposome therapy for interstitial cystitis, Int. J. Urol., 24, 262, 10.1111/iju.13317 · DOI
  53. Janicki, 2016, Potential effect of liposomes and liposome-encapsulated botulinum toxin and tacrolimus in the treatment of bladder dysfunction, Toxins, 8, 81, 10.3390/toxins8030081 · doi:10.3390/toxins8030081
  54. Chancellor, 2001, Future trends in the treatment of urinary incontinence, Rev. Urol., 3, S27
  55. Killinger, 2013, Pain in interstitial cystitis/bladder pain syndrome: do characteristics differ in ulcerative and non-ulcerative subtypes?, Int. Urogynecol. J., 24, 1295, 10.1007/s00192-012-2003-9 · doi:10.1007/s00192-012-2003-9
  56. Laird, 2001, A new model of visceral pain and referred hyperalgesia in the mouse, Pain, 92, 335, 10.1016/S0304-3959(01)00275-5 · DOI · Paper page
  57. Birder, 2018, Animal modelling of interstitial cystitis/bladder pain syndrome, Int. Neurourol. J., 22, S3, 10.5213/inj.1835062.531 · DOI
  58. Tyagi, 2014, Pathophysiology and animal modeling of underactive bladder, Int. Urol. Nephrol., 46, 11, 10.1007/s11255-014-0808-9 · DOI

Cited by

See all 41

Metadata

Authors
Jensen, M. M., Jia, W., Schults, A. J., Isaacson, K. J., Steinhauff, D., Green, B., Zachary, B., Cappello, J., Ghandehari, H., & Oottamasathien, S.
Venue
Biomaterials
Publisher
Elsevier BV
Published
2019-10
Volume
217
Pages
119293
ISSN
0142-9612
Cited by
41
References
2
Language
en
Licence
Funders
  • National Science Foundation
  • National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome. https://app.cochat.ai/papers/10.1016/j.biomaterials.2019.119293
The paper
Jensen, M. M., Jia, W., Schults, A. J., Isaacson, K. J., Steinhauff, D., Green, B., Zachary, B., Cappello, J., Ghandehari, H., & Oottamasathien, S. (2019). Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome. Biomaterials. https://doi.org/10.1016/j.biomaterials.2019.119293

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.